gc5131

GC5131 is a hyperimmune globulin drug developed as a plasma-derived therapy for COVID-19. It is produced by GC Pharma (formerly Green Cross Corporation) using blood plasma collected from individuals who have recovered from COVID-19, concentrating antibodies to provide passive immunity against the virus. The mechanism of action involves supplying high levels of neutralizing antibodies to help control SARS-CoV-2 virus infection, particularly in patients with severe or critical illness. Clinical studies have focused on its use in hospitalized patients with COVID-19, though evidence suggests it may be more effective if administered early in the disease course rather than in critically ill cases[1][2][3][4][5].

Other names

gc5131gc-5131gc 5131